Kezar Life Sciences Inc expected to post a loss of 28 cents a share - Earnings Preview

Kezar Life Sciences

13/03/2023 11:02

* Kezar Life Sciences Inc  KZR.OQ   KZR.O  is expected
to show no
change in quarterly revenue when it reports  results on March 15
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Kezar Life Sciences
Inc
is for a loss of 28 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kezar Life
Sciences Inc is $18.5​, above​ its last closing price of $4.64.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.27       -0.27      -0.25     Beat    7.5
 Jun. 30 2022  -0.27       -0.27      -0.25     Beat    9
 Mar. 31 2022  -0.28       -0.28      -0.26     Beat    8​
 Dec. 31 2021  -0.33       -0.30      -0.25     Beat    15.7
 ​​Sep.        -0.26       -0.26      -0.28     Missed  -6.3
 30 2021                                                
 Jun. 30 2021  -0.27       -0.26      -0.25     Beat    3.8​
 Mar. 31 2021  -0.24       -0.24      -0.25     Missed  -5.9
 Dec. 31 2020  -0.25       -0.23      -0.22     Beat    4.5
 This summary was machine generated March 13 at 11:01 GMT.  All
figures in US dollars  unless otherwise stated